Advanced Bifurcation Systems Closes Series A Financing

December 22, 2020—Advanced Bifurcation Systems, Inc. (ABS), a clinical-stage medical devices company based in Livermore, California, announced the closing of an $11 million Series A equity financing by Cedars-Sinai Medical Center in Los Angeles, California, and a leading medical device manufacturer that was not disclosed in the company’s announcement.

According to the announcement, ABS is developing a stent delivery system designed to efficiently treat all coronary bifurcation lesions in coronary angioplasties. The company’s device includes a modular, independently movable dual-catheter system for provisional side-branch stenting as well as full bifurcation stenting with ABS’s crimping technology that allows for partial crimping of the main stent.

The company stated that the ABS system has been evaluated through bench testing, animal implants, and 10 human implants at three international medical centers—all with successful results. Proceeds from the financing will be used to conduct in-human testing in accordance with the FDA premarket approval application process. Additionally, the funding will enable ABS to seek an FDA investigational device exemption for an early feasibility study, which are preconditions to the commencement of ABS’s pivotal trial.

ABS was founded by Mehran Khorsandi, MD, and medical devices engineer Henry Bourang. Dr. Khorsandi is an interventional cardiology and endovascular interventionalist at the Center for Advanced Cardiac and Vascular Interventions at Cedars Sinai.